{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-002877","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.859705+00:00","generated_at":"2026-05-15T01:24:47.757890+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aptose delays closing of Hanmi arrangement; targets May 2026 for completion","bullets":["Closing delayed as Korean regulatory approvals remain in progress; parties do not anticipate prevention.","Hanmi will acquire all outstanding Aptose shares at C$2.41 per share, a 28% premium to C$1.88 VWAP.","Transaction originally announced Nov 19, 2025; closing expected in May 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002877","json":"https://secwatch.observer/filing/0001171843-26-002877.json","markdown":"https://secwatch.observer/filing/0001171843-26-002877.md","text":"https://secwatch.observer/filing/0001171843-26-002877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184326002877/0001171843-26-002877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184326002877/f8k_042926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:24:47.757890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}